MAM-06.301- anti-allergic compound

Marinomed’s compound, MAM-06.301, is an allergy compound that provides an effective and safe alternative to corticosteroids and anti-histamines.

MAM-06.301 has long been known in different indications for topical and oral use and therefore, the compound is considered to be safe for humans. Marinomed has discovered that this compound is also efficacious in allergy.

The properties of MAM-06.301 have been evaluated in mouse-models for skin allergy, allergic asthma and allergic contact dermatitis. A comparison with dexamethasone showed equal efficacy of MAM-06.301.

 Figure 1 - Anti-allergic and dose-dependent efficacy of beta-escin in the murine PCA model.

For PCA induction, anti-TNP IgE (2.5µg) was injected intradermally into the dorsal skin at 6 independent spots. After 15 min, mice were challenged with intravenous injection of 50 µg DNP-BSA supplemented with 1 % Evans blue dye. Blue stained skin areas were quantified from digital photographs 15 min after challenge. (A) SKH1-mice were pre-treated i.p. with vehicle (10 ml/kg, n = 21), dexamethasone (dex, 3 mg/kg, n = 5) or beta-escin (escin, 3 mg/kg, n = 12) 6 h prior application of antigen. (B) Different concentrations of beta-escin (n = 4-12) were given i.p. 6 h prior challenge. For each mouse the mean of 6 spots was calculated. Based on these values the mean ± SEM was determined for each group, normalized to the vehicle control group (equals 100 %) and represented as column or point in the graphs (A) and (B), respectively. Significant differences between the treatment groups and the vehicle group are indicated with: * p<0.05 and *** p<0.001.

Source: Beta-escin has potent anti-allergic efficacy and reduces allergic airway inflammation (Ines Lindner, Christiane Meier, Angelika Url, Hermann Unger, Andreas Grassauer, Eva Prieschl-Grassauer and Petra Doerfler), BMC Immunology 2010. 

In addition, an in-vivo model for skin allergy in pigs, where MAM-06.301 was given orally, suggests efficacy as treatment against severe allergic conditions like asthma.

Development opportunities with MAM-06.301: 

• Oral formulation: Treatment against severe allergic conditions such as allergic asthma and allergic contact dermatitis
• Nasal spray: Treatment against allergic rhinitis (hayfever)